MedPath

Examination for the effect of combination therapy with Eldecalcitol and Alendronate in primary osteoporotic patients

Phase 4
Conditions
Osteoporosis
Registration Number
JPRN-UMIN000008191
Lead Sponsor
Showa University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who are diagnosed as contraindication of Alendronate treatments 2. Patients who are diagnosed as contraindication of Eldecalcitol treatments 3.Patients who have taken osteoporosis treatments other than Alendronate 4.Patients with cancer 5. Patients who are inappropriate for this study by physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change of lumbar spine bone mineral density
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath